source
- Boston Scientific cuts guidance again after unveiling restructuring planBoston Scientific is cutting its financial guidance for the second quarter in a row as it gears up for a tough six months ahead.Fierce Biotech · 10h ago↗ source
- FDA advisory panel votes 9-3 against Capricor's Duchenne therapy deramiocelDuring an FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting, reviewers focused on the Phase 3 HOPE-3 trial's secondary cardiac endpoint and described the data as very fragile. The…